A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...

GOTHENBURG, SE / ACCESS Newswire / January 23, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 23, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company dis ...

GOTHENBURG, SE / ACCESS Newswire / January 23, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 23, 2025 - IRLAB Therapeutics AB , a company discovering and developing ...

In a report released yesterday, Faisal Khurshid from Leerink Partners maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report), ...

Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

Tardive dyskinesia is a drug-induced neurological disorder characterized by involuntary movements of the face and body. The condition develops as a side effect of long-term use of antipsychotics and ...

Alzheimer's, the most common form of dementia, is thought to affect 50 million people worldwide and usually starts after age 65 - Copyright AFP/File Philippe LOPEZ ...

20 The most common levodopa-induced dyskinesias occur at the time of the maximal plasma levodopa concentration and clinical response ('peak-dose dyskinesia'). Any part of the body can be involved ...

In early, levodopa-naive PD patients, Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested (target maintenance dose Stalevo 100 four-times daily given ...

However, long-term treatment with levodopa induces involuntary and uncontrollable movements known as levodopa-induced dyskinesia. A study published in the journal Brain has uncovered new findings ...